Epidemiological aspects of gastric adenocarcinoma: are predictive diagnostics and targeted preventive measures possible? by Krister Sjödahl & Jesper Lagergren
REVIEW ARTICLE
Epidemiological aspects of gastric adenocarcinoma:
are predictive diagnostics and targeted preventive measures
possible?
Krister Sjödahl & Jesper Lagergren
Received: 22 April 2010 /Accepted: 5 July 2010 /Published online: 22 July 2010
# European Association for Predictive, Preventive and Personalised Medicine 2010
Abstract The incidence of gastric cancer has witnessed
major changes over the past decades. Until recently, gastric
cancer was a common malignancy in most countries. A
striking decline in incidence in most Western populations
has occurred since the 1970s, and elucidating the detailed
causes for this trend can potentially be of great value for
targeted preventive measures. Furthermore, it can add to the
understanding of malignant disease and prevention in
general. Moreover, the absolute number of cases worldwide
is predicted to increase during many years to come. Gastric
cancer is typically diagnosed at an advanced stage in
symptomatic patients, and there are often no effective
curative or palliative or therapeutic options. This fact
highlights the need for research aiming to increase our
understanding of the etiology of this cancer, facilitating the
design of successful targeted preventive strategies for
different populations. The future outlook in terms of
decreasing gastric cancer deaths would be to identify such
intelligent diagnostic tools. In this article, we present a
summary of the epidemiology of gastric cancer, with
special focus on its etiology.
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Introduction
In recent years, etiological research concerning gastric
cancer has been dominated by the role of the bacteria
Helicobacter pylori (H. pylori). About half of the world’s
population is infected with this bacteria, and it is becoming
increasingly clear that also other environmental factors are
of critical importance in gastric cancer causation, such as
cigarette smoking, diet, and gastroesophageal reflux. The
risk might be influenced both through interaction with this
bacterium and by affecting the risk independently.
Gastric cancer incidence
Gastric adenocarcinoma is currently the fourth most
common malignancy globally and the second leading cause
of cancer-related death [1]. Only cancer of the lung, breast,
and colon are more common. It has been estimated that
934,000 new cases of gastric cancer occur every year, and
that 700,000 people die annually from this disease [1],
representing more than 10% of all cancer deaths. Two
thirds of the patients live in developing countries. There has
been a marked fall in its incidence in developed countries
since the 1930s, which has been described as one of the
greatest medical triumphs of the last century. The develop-
ment reflects a change in incidence rather than earlier
diagnosis, better treatment, or changes in definition [2]. The
authors of a recent study concluded that steady downward
trends in gastric cancer mortality worldwide have continued
during the last decades [3]. However, as a consequence of
the aging and growing global population, it is predicted that
the absolute number of gastric cancer cases will continue to
increase up to the year 2050 [2, 4]. Gastric cancer is closely
associated with age, the peak incidence being between the
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5th and 7th decades of life. There is an overall male
predominance, with 2–3 males per every female affected,
but the declining incidence has occurred in both sexes.
However, increased attention has been directed to what
seems to be an increasing trend in incidence of cancer in the
gastric cardia. Classification of tumors of the proximal
stomach is potentially unreliable and clinicians might use
different definitions when reporting to cancer registries, but
the acceleration in the incidence of cardia cancer seems to
be real [5]. A widely used system of classification was
proposed by Siewert in 1998 [6]. For cardia cancer, there is
an even more pronounced male to female ratio, around 6:1,
and this cancer is more common among whites and in
Western countries [7–9]. These striking epidemiological
patterns are still only partly explained. Elucidation of
modifiable causes of these trends could potentially lead to
an acceleration of the decline in the incidence of non-cardia
gastric cancer, as well as a reverse of the opposite incidence
trend regarding cardia cancer.
Globally, there is a 10-fold variation in reported national
incidence rates of gastric cancer [1]. However, underesti-
mation from less developed parts of the world where health
care availability, diagnostic methods, and cancer reporting
practices exhibit shortcomings render valid comparisons
difficult. High incidences of gastric cancer have been noted
in Japan, South Korea, Central and South America, and
Eastern Europe, while low incidence rates have been
reported from parts of East Asia, Scandinavia, Western
Europe, North America, Australia, and regions in Africa. In
2002, the worldwide average estimate of age-adjusted
incidence was 22.0 per 100,000 person-years in men and
10.3 per 100,000 person-years in women [1]. In many
populations, the decline in incidence of gastric cancer has
followed a birth-cohort phenomenon, i.e. the incidence rate
in subsequent generations tend to fall, implying shared
temporal risk factors [10].
Histology of gastric cancer
Adenocarcinomas represent more than 95% of gastric
neoplasms. Other types include stroma cell tumors (GIST),
lymphomas, lipomas, carcinoids, adenomas, and metasta-
ses. Laurén suggested that gastric adenocarcinoma cases
should be divided into two histologically distinct groups: 1)
the intestinal type, with glandular epithelium composed of
absorptive cells and goblet cells, and 2) the diffuse type,
with poorly differentiated small cells in a dissociated
noncohesive growth pattern [11, 12]. In addition, mixed
tumors occur, representing a combination of the intestinal
and diffuse types [12, 13]. The intestinal type is more
common than the diffuse type in areas with a high
incidence of the disease [14].
There are marked clinical and genetic differences
regarding the two histological types of gastric adenocarci-
noma, and much evidence supports the possibility of
separate disease etiologies [2, 15]. However, no clear-cut
differences in the pattern of risk factors have been revealed
in studies where the two histological types of gastric cancer
have been analyzed separately [16–18]. A wide range of
genetic and epigenetic abnormalities, including point
mutation, loss of heterozygosity, microsatellite instability,
and hypermethylation, are described in the intestinal
type and its precursor lesions [19]. The diffuse type is
characterized by absence of such pre-neoplastic lesions, and
mutation or epigenetic silencing of the E-cadherin gene
seems to be an important carcinogenic event [19, 20].
Furthermore, the diffuse type is more frequent in younger
individuals and has a more equal male-to-female ratio [12].
Much of the decline in the incidence of gastric cancer
seems to be the result of a falling rate of new cases of the
intestinal type. A classical hypothesis regarding the
pathogenesis defining the intestinal type was presented in
1975 by Correa et al. [21]. According to this suggestion,
which has been slightly changed during the years, the
development of gastric cancer follows the sequence: H.
pylori—superficial gastritis—atrophic gastritis—intestinal/
complete metaplasia—colonic/incomplete metaplasia—dys-
plasia—carcinoma [21, 22]. The progression of these
lesions follows a pattern of steady state, with episodes of
progression to more advanced lesions, and episodes of
regression to less advanced lesions. Gastric atrophy leads to
loss of parietal cells and hyposecretion of gastric acid, in
turn leading to an increased pH of the gastric juice,
facilitating proliferation of anaerobic bacteria which reduce
nitrate to nitrite, abundant in many foods. From nitrite,
carcinogenic N-nitrosamines can be generated. Reducing
agents such as ascorbic acid prevents the formation of
nitrosated and nitrated compounds [23]. Intramucosal
production of carcinogenic nitrosamines has also been
suggested [24]. There have been concerns that widespread
treatment with proton pump inhibitors could lead to an
increase in gastric cancer [25, 26], since such therapy
causes corpus-dominant gastritis in patients with H. pylori
infection which is associated with hyposecretion [27].
However, there is no strong support for such an adverse
effect of proton pump inhibitors [28].
It is quite possible that the intestinal type of cancer arises
in a gastric mucosa that has undergone a sequence of
mutations and histopathological changes that may have
started in the first decades of life. Although the exact
mechanisms leading to neoplastic transformation remain
largely unknown, focus has been directed to the possibility
that “oxidative stress” might be crucial in the carcinogenic
process [29, 30]. This implicitly suggests that counteractive
“antioxidant” measures could protect the DNA of the
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mucosal cells from a continuous barrage of genotoxic
agents. Recently, intriguing evidence that bone marrow-
derived stem cells are involved in gastric cancer develop-
ment has become available [31, 32]. Peripheral tissue stem
cells in the gastric mucosa might be damaged by chronic
inflammation [31]. This in turn leads to the recruitment and
permanent engraftment of bone marrow-derived stem cells
into the tissue stem cell niche. With ongoing inflammation
and injury these cells are exposed to an abnormal tissue
environment characterized by elevated cytokine and growth
factor levels which are likely to initiate differentiation, but
fail to regulate growth programs appropriately and instead
progress through stages of metaplasia and dysplasia [31,
32].
Etiology of gastric cancer
Environmental factors are of greater importance than
genetic factors in gastric cancer etiology [15]. Familial
clustering of cases does occur, suggesting a prominent
genetic causal role in some cases, but exposures other than
hereditary generally play a more decisive role in the
population at large. Supporting these findings is the
observation that first generation migrants from high-
incidence areas sustain the risk of their country of origin
but that the incidence rate in subsequent generations falls
[33]. This pattern is also seen, for example, for colon
cancer, but in the case of gastric cancer this adaptation
seems to be slower. These observations strengthen the
hypothesis that factors acting early in life could have a very
important role in gastric carcinogenesis.
Older age is linked with increased risk. In this context it
is a proxy for degenerative changes and accumulated DNA
damage. In addition, gastric cancer occurs predominantly in
lower socioeconomic groups. This inverse relation with
socioeconomic status is observed in almost every popula-
tion [34, 35], but there is no exact correlation to the national
level of economic development [1].
Genetic causes
Some 10% of patients with gastric cancer have a family
history of this disease, and there is a slightly greater disease
correlation between identical rather than fraternal twins
[36]. Nevertheless, many genes that underlie inherited
cancer syndromes have a more widespread role in sporadic
cancers, as a result of somatic mutations that arise during
tumor initiation or progression [20]. The discovery of germ
line mutation at the E-Cadherin gene, coding for a cell-
adhesion protein, in familial gastric cancers of the diffuse
histological subtype, is an example of progressing under-
standing of gastric cancer genetics. It has also been shown
that expression of E-Cadherin decreases along Correa’s
cascade [37], and that H. pylori infection is associated with
down regulation of E-Cadherin [38, 39]. Other studies have
shown intriguing associations between polymorphisms in
genes coding for pro-inflammatory cytokines and risk of
gastric cancer [40]. Mutations in the Interleukin-1B gene
have been considered to be among the most crucial,
although a recent meta-analysis did not provide any support
for such an association [41].
Helicobacter pylori
The Nobel Prize in Physiology or Medicine in 2005 was
awarded to the Australian physicians Barry J. Marshall and
J. Robin Warren “for their discovery of the bacterium
Helicobacter pylori and its role in gastritis and peptic ulcer
disease” [42]. This remarkable discovery was made in
1983, and since then it has become increasingly clear that
this bacterium also plays a prominent causative role in the
etiology of gastric cancer. In 1994, IARC classified H.
pylori as a definite class 1 carcinogen [43]. As conflicting
results accumulated, some scientists came to believe that
this decision was made somewhat prematurely, but added
together, the results obtained over the last 20 years strongly
indicate that H. pylori plays a true causal role in gastric
cancer etiology [44–46]. The average strength of the
relation as determined by meta-analyses produces an effect
size of about a doubled risk [47–49]. H. pylori infection has
been found in human stomachs all over the world. Most
infections seem to be acquired in childhood, typically
lasting for many decades or for lifetime [50]. The mode of
transmission is not completely understood, but the fecal-
oral bacterial transmission route is probably the most
important [51]. Approximately half of the global population
is infected, and the occurrence is strongly correlated with
low socioeconomic status [52]. In some low-income
countries, 70–90% of the inhabitants are infected, whereas
in high-income countries, the prevalence is 25–50%. H.
pylori infection is associated with an inflammation of the
gastric mucosa. The exact mechanisms by which this
bacterium causes gastric cancer remain to be elucidated
[53], but the clinical outcome of this infection is determined
by an interplay between H. pylori, host derived factors, and
environmental factors [32]. In some areas of the world a
very high prevalence of H. pylori infection runs parallel
with low gastric cancer rates [54]. Many bacterial virulence
factors that might play a role in H. pylori related disease
outcomes have been identified. Cytotoxin associated gene
A (CagA) positive strains are, for example, associated with
a further increased risk of gastric adenocarcinoma [53]. In
the Western countries, around 60% of H. pylori isolates
possess CagA, compared to virtually all isolates in Japan
[55]. As a result of polymorphisms coding for this virulence
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factor, populations infected with East Asian CagA-positive
strains may be at an especially great risk for gastric cancer
[56]. However, antibodies against CagA seem to persist
longer in serum than conventionally used antibodies
utilized for bacterial detection. This could partly explain
the stronger observed association between CagA positive
strains and gastric cancer [57, 58]. A strong, but ineffective,
immune response is typically associated with H. pylori
infection. Genetic polymorphisms influence individual
variation in the extent and pattern of cytokine response,
and thus seem to contribute to the clinical outcome of the
individual [59]. It has been proposed that environmental
factors and host related factors may be more important than
H. pylori virulence factors in producing gastric cancer [60].
In line with this suggestion is the observation of a rapid
change in the worldwide incidence of this malignancy. This
could potentially be explained by a similar decrease in the
prevalence of a particular bacterial virulence factor, but
there is evidence against this hypothesis [61]. H. pylori can
be diagnosed by a variety of tests and is readily treated with
antibiotics, and recent findings from a Japanese randomized
study showing that gastric cancer rates are substantially
reduced, but not abolished, by H. pylori eradication have
intensified the debate of preventive eradication [62]. There
are still no preventive vaccinations [63]. Before recom-
mendations of preventive strategies are suggested, it is
important to evaluate possible negative effects of such
attempts. There are indications of an inverse relation
between H. pylori infection and risk of esophageal
adenocarcinoma, a cancer with a most rapidly increasing
incidence, which is one reason to maintain a prudent
attitude toward grand-scale vaccination programs [58, 64,
65]. Furthermore, the issue of antibiotic resistance must be
considered [66]. Better sanitation and improved public
health has probably led to the observed decline in the
prevalence of H. pylori infection in the industrialized
world.
Fruit and vegetables
There is substantial evidence that a diet rich in fruit and
vegetables is protective against gastric cancer [67, 68].
Prospective studies have repeatedly shown significant
reductions in the risk of gastric cancer in association with
high consumption of fruit and vegetables [69–71]. Findings
in numerous case–control studies have also supported this
protective effect [18, 72, 73]. Carcinogenic N-nitrosamines
can, however, be generated from nitrite. This anion is
formed from reduction of nitrate, abundant in many foods.
For people who consume a typical Western diet, vegetables
account for 60–80% of the daily intake of nitrate [74]. The
highest concentrations of nitrate are present in leafy green
vegetables such as salad and spinach, although the nitrate
levels in vegetables can vary considerably depending, e.g.
on the use of nitrogen fertilizers [75]. Small amounts of
nitrite also come from processed meat [74].
Tobacco smoking
The relation between tobacco smoking and gastric cancer
has been the focus of many studies over the years, and
taken together these studies indicate that smoking is a
moderate risk factor [76]. In a meta-analysis of the relation
between smoking and gastric cancer, the excess risk
associated with smoking was estimated to be 50–60% [77].
The relative risk was higher in men (59%) than in women
(11%). If this association is true, the high prevalence of
tobacco smoking in the world suggests that a substantial
number of gastric cancer cases (80,000) could be due to
smoking [77]. A recent systematic review and meta-analysis
only considering cohort studies, showed that the risk of
gastric cancer is increased by 60% in male smokers and by
20% in female smokers, compared to never smokers, and
that the associations are weaker in former smokers [78]. A
difference in risk depending on the anatomical location of
the tumor within the stomach is a possibility. Some
prospective studies have indicated that non-cardia gastric
cancer is associated with a stronger risk [79], whereas
others, e.g., a large prospective study [80], have shown the
opposite. There is some evidence of a strongly increased
risk among people with CagA-positive H. pylori strains
who smoke, thus suggesting interaction between these
exposures in relation to gastric cancer development [81].
Smoking is a risk factor typically acquired early in life, and
some data indicates that earlier onset of smoking is a risk
factor per se [82]. It is biologically plausible that that the
anti-carcinogenic defence mechanisms more easily become
overwhelmed in a younger organism. The same kind of
association has been demonstrated regarding smoking and
lung cancer [83].
Alcohol
On the basis of most previous research, alcohol consump-
tion seems to be an unlikely cause of gastric cancer [17, 68,
84–86], although some results are partly contradictory [82,
86, 87].
Obesity
Although high Body Mass Index (BMI) is linked with an
overall increase in the risk of cancer in general, and is an
established and strong risk factor for gastric cardia
adenocarcinoma [84, 88, 89], results from case–control
studies addressing the risk of gastric cancer have rather
indicated a link between low BMI and gastric cancer [90–
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93], while prospective studies have yielded contradictory
results [84, 89, 94–102]. Taken together, obesity does not
seem to play a major role in the etiology of gastric cancer
distal to the cardia.
Gastroesophageal reflux
Cancer of the gastric cardia is positively associated with the
exposures gastroesophageal reflux, obesity and tobacco
smoking [103]. Obesity and reflux are associated with each
other, but both are also independent risk factors of cardia
cancer [104].
Physical activity
Only in a few studies has physical activity been investigat-
ed in relation to risk of gastric cancer. One prospective
study has shown an increased risk associated with measures
of increased activity [105], while others have not shown any
association [106, 107]. A recent prospective cohort study in
Norway, on the other hand, indicated that recreational
physical activity protects against gastric cancer [101].
Another large prospective study investigating gastric cancer
in relation to physical activity in a cohort of US men and
women found evidence of a reduced risk, the inverse
association with physical activity was strongest for gastric
non cardia adenocarcinoma [108]. A biological mechanism
linking physical activity to a decreased risk of gastric
cancer risk is lacking, but multiple pathways are plausible,
e.g. a genetic predisposition of habitually active persons
[109], an improved immune function with increases in level
and activity of circulating tumor-inhibiting natural killer
cells [110], up-regulation of the activity of free scavenger
systems and oxidant levels [111, 112], and decreased levels
of insulin and insulin-like growth factors [113].
Salt intake
The hypothesis that high dietary salt intake increases the
risk of gastric adenocarcinoma was spawned in the 1960s,
and evidence has gained support from ecological, case–
control and cohort studies, mainly from high-incidence
Asian countries, over the past decades [67, 68, 114, 115].
The falling incidence of this malignancy has coincided with
the spread of refrigeration, which should be inversely
associated with salting and other salt-based methods of
food preservation [68]. Salt is thought to increase the risk of
gastric adenocarcinoma through induction of chronic
inflammation of the gastric mucosa. A high salt concentra-
tion in the gastric mucosa could lead to diffuse erosion, and
the induced proliferation in the inflamed environment could
promote the effect of carcinogens derived from food [22].
However, few prospective studies have assessed the
association of salt intake with the risk of gastric adenocar-
cinoma, particularly in Western societies, and the results
from these studies have been inconsistent, thus leaving
some doubt about the role of salt in gastric cancer etiology
[114]. The authors of a recent review of salt consumption
and gastric cancer risk concluded, however, that limitation
on salt and salted foods is a practical strategy for preventing
gastric cancer [116].
Occupational exposures
Many studies of gastric cancer have been conducted within
occupational settings. There is evidence that occupations in
coal and tin mining, metal processing, particularly of steel
and iron, and rubber manufacturing industries lead to an
increased risk of gastric cancer [117]. Other “dusty”
occupations have also been implicated, but the evidence is
not strong [118–121]. Most of these investigations have
used job titles as a proxy for exposure of specific
carcinogenic exposures [117], and there has often been a
lack of information regarding potential confounding factors.
Therefore, the potential harmful effect of several specific
occupational exposures remains uncertain.
Socioeconomic status
Low socioeconomic status has consistently been shown to
be associated with an increased risk of gastric cancer [2,
122], and recent data also supports a similar link with
cardia cancer [99, 123]. Socioeconomic status is a potential
proxy for a number of factors, e.g. lifestyle patterns, dietary
habits, BMI, H. pylori infection and smoking habits [124].
Some researchers also stress the potential influence on
disease risk of commercial marketing activities, relative
social status, levels of income and education (often used as
proxy measures for socioeconomic status), access to the
health care system, and the strength or absence of social
networks [125]. Following these lines of argument, the
environmental factor H. pylori which has attracted most
attention lately could be viewed as one of the causative
agents underlying the statement “poverty is a carcinogen.”
Female sex hormones
The yet unexplained 2–3:1 male predominance in gastric
cancer has prompted the hypothesis that premenopausal
women are protected from developing gastric adenocarci-
noma by virtue of their high endogenous estrogen exposure.
The global finding that women develop the intestinal type
of gastric adenocarcinoma on average 10–15 years later
than men [126], and that the incidence of this type of cancer
increases after the menopause, has sparked an interest in
further investigations. One prospective study indicated that
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hormone replacement therapy with estrogens is associated
with a risk reduction of gastric cancer, particularly of the
non-cardia site [127]. Other studies have shown further
indications favoring such an association [128]. More
research is however needed before such a potential effect
is proven.
Other causes
Prior gastric surgery for benign conditions has been shown
to be associated with gastric cancer [129, 130]. Twenty
years after gastric resection for a benign disease the relative
risk has been found to be increased. The risk of cancer in
the gastric remnant (“stump” cancer) can relate to the
production of nitrosamines by bacteria in the relatively
hypoacidic stomach remnant or as a result of long-term bile
damage to the gastric mucosa. However, since peptic ulcer
disease is also related to gastric cancer, the relation between
gastric surgery for this benign condition and gastric cancer
is difficult to establish [131].
There is an excess risk of developing gastric adenocar-
cinoma in persons with pernicious anemia. This appears to
be an autoimmune disease leading to chronic atrophic
gastritis type A (type B is represented by H. pylori related
gastritis) located mainly in the corpus of the stomach [132].
Atrophic gastritis is a stage in Correa’s model of gastric
carcinogenesis and should be regarded as a premalignant
state if found in a patient, even in the absence of H. pylori
infection.
Epstein-Barr virus may play an etiological role in a
subset of gastric adenocarcinomas [133, 134]. This virus is
ubiquitous in all human populations, and about 10% of
gastric cancers throughout the world show monoclonal
proliferation of Epstein-Barr virus-infected cells [135]. In
contrast to Burkitt lymphoma and nasopharyngeal carcino-
ma, which are endemic in Africa and Southeast Asia,
Epstein-Barr-positive gastric cancers are non-endemic and
distributed more evenly throughout the world [135].
Lymphoepithelioma-like gastric cancer might be the main,
if not the only, gastric cancer positive for Epstein-Barr
cancer [136].
A 20% increase in relative risk of gastric cancer among
people with blood group A, compared to those with blood
group 0, was reported already in 1953 [137]. This difference
has been attributed to the nature of mucopolysaccharide
secretion in the stomach of blood group A individuals, and
to a greater susceptibility to ingested carcinogens.
Follow-up of atomic bomb survivors, exposed to
ionizing radiation, has revealed an increased risk of gastric
cancer, as well as of cancer at many other sites [96, 138].
Patients with primary immunodeficiency are at increased
risk of developing hematological malignancies, and some-
times also carcinoma. The risk of developing chronic
atrophic gastritis, metaplasia, and distal cancer seems to
be especially pronounced [139].
Prognosis
Almost two thirds of all cases of gastric cancer occur in the
developing world. A diagnosis of gastric cancer in Western
countries is brightened with some hope of cure, while in
developing countries the diagnosis is almost without
exception terminal. However, the prognosis in the Western
hemisphere is also disappointing, and the estimated 5-year
survival in Western societies is only 24–27% [2, 140]. There
has been only a slight improvement during the past 20–
30 years, despite all attempts to improve the survival with,
e.g., different surgical techniques and various combinations
of chemotherapeutic drugs [141]. The individual prognosis
is highly dependent on tumor stage at presentation. In
Japan, screening is carried out for gastric cancer, resulting
in detection of up to 40% of these cancers at an early stage
with much better prognosis as a result [142]. In Europe, the
proportion of early gastric cancer is less than 15% [142].
Gastric cancer prevention
Chemoprevention trials of gastric cancer have been
attempted with varying success. In a Chinese trial, a
reduction in gastric cancer mortality and incidence was
found after 5 years in persons who received daily
supplementation with beta-carotene, vitamin E, and seleni-
um [143]. A study in a low-risk population of male
physicians showed no effect of beta-carotene after an
average of 12 years of follow-up [144]. Several studies
have shown prevention of the progression of preneoplastic
mucosal changes after H. pylori eradication and antioxidant
supplementation [145–147]. In a recent clinical trial in a
high-risk area in Venezuela, supplementation with antiox-
idant vitamins was not found useful in prevention of gastric
precancerous lesions [148]. A trial in a high-incidence area
in Colombia studied various interventions on precancerous
lesions at baseline. The treatment arms included H. pylori
therapy, ascorbic acid supplements, beta-carotene supple-
ments, and all possible combinations of these three
interventions. All of these interventions resulted in signif-
icant regression of existing premalignant lesions in a pattern
not clearly indicating the relative effectiveness of the
individual agents [149]. The role of conventional nonsteroi-
dal anti-inflammatory drugs (NSAIDs), cyclooxygenase 2
inhibitors (COX-2), and aspirin as chemopreventive agents
remains controversial [150, 151]. In observational studies
investigating the relation between these drugs and gastric
cancer, confounding by indication is often a serious source of
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bias. However, NSAIDs might exert preventive effects
against gastric cancer [152-154]. Unfortunately, no random-
ized trials with gastric cancer as outcome have yet been
completed.
Screening for gastric cancer has been reported to be
effective in some populations, but this is not universally
accepted [155]. There is currently no biomedical marker of
progression of the precancerous process which can
reliably be used in screening programs. Screening with
pepsinogen serum levels has been suggested as a comple-
ment to H. pylori antibody titers for high-risk patients
[156, 157]. Recent advances related to human cytokine
polymorphisms should, in the near future, allow the design
and implementation of more targeted, large-scale screening
programs aimed at identifying persons at the highest risk
of gastric cancer. Interventions may become more specific
if genetic polymorphisms are identified with the potential
to affect cancer risk in combination with environmental
exposures. These are more likely to concern premalignant
lesions than invasive cancer.
Some authors consider that a reduction in dietary salt
intake, an increase in the consumption of fruit and
vegetables, and avoidance of tobacco smoking are effective
means to reduce the incidence of gastric cancer [158]. The
unplanned prevention that has taken place in the West is
probably a result of a better overall socioeconomic
standard, leading to a reduced prevalence of H. pylori,
and of widespread use of refrigeration, less consumption of
salted foods, and increased intake of fresh fruit and
vegetables. By elucidating the factors explaining the
decline in incidence, this process could potentially be
accelerated, making it more effective, e.g., by acting against
exposures that counteract this trend. A healthy and active
attitude of cancer-epidemiological vigilance should be
maintained to ensure maintenance of the falling incidence
of gastric cancer.
Concluding remarks
Tremendous effort has been made to shed light on the
causation of gastric cancer. But there is still a need for
research aiming to increase our understanding of the
etiology of this cancer, facilitating the design of successful
targeted preventive strategies for different populations. The
future outlook in terms of decreasing gastric cancer deaths
would be to identify such intelligent diagnostic tools.
A foreseeable consequence of methodological advan-
ces in assessing gene-environment interactions is that
people might be characterized according to their inherent
cancer susceptibility. The availability of such information
would raise ethical issues regarding, e.g., the protection
of workers from occupational hazards. This is also a
valid argument regarding lifestyle factors in other
sections of a population and should be kept in mind
when deciding to test for newly identified potentially
critical genetic variants. It is conceivable that every
person in a population is at much higher risk than most
other persons for a specific cancer type, and the question
should always be discussed on an individual level before
a decision is made to take the test or not. For some
people, knowledge can sometimes be a burden and
would in retrospect not really have wanted to know that
they are at a high risk of developing a disease or that
they have attracted a pre-malign condition. The field of
genetic epidemiology is rapidly evolving and future
research toward an understanding of the etiology and a
targeted prevention of gastric cancer will move in the
direction of molecular epidemiology to a greater extent.
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